A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Inclusion Criteria: * Subjects with a histopathological or cytologically diagnosis of HCC * Subjects who have undergone a curative resection * High risk for HCC recurrence as protocol defined * No previous systematic treatment and locoregional therapy for HCC * Child-Pugh Score, Class A * ECOG performance status 0 or 1 * Full recovery from surgical resection * Adequate organ function * Absence of major macrovascular invasion * No extrahepatic spread * Life expectancy of at least 6 months Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC * Evidence of residual, recurrent, or metastatic disease * Known history of serious allergy to any monoclonal antibody * History of hepatic encephalopathy * Tumor thrombus in portal vein or superior mesenteric vein or inferior caval vein * Portal hypertension with bleeding esophageal or gastric varices within 6 months prior to initiation of treatment * Any bleeding or thrombotic disorder within 6 months prior to initiation of treatment * Any active malignancy within 2 years prior to the start of treatment * Active or history of autoimmune disease * Other acute or chronic conditions, psychiatric disorders, or laboratory abnormalities that may increase the risk of study participation * Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or other immunotherapy * Pregnant or lactating women